Search results
Results From The WOW.Com Content Network
Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market in record time and quickly generating blockbuster revenue from it. Since ...
Shares of Moderna (NASDAQ: MRNA) zoomed as much as 33.3% higher this week, according to data from S&P Global Market Intelligence. The maker of vaccines, including the mRNA vaccine for COVID-19, is ...
Thursday, Moderna Inc (NASDAQ:MRNA) unveiled key updates at its annual R&D Day by reducing annual R&D spending by $1.1 billion by 2027, enabling a focus on ten prioritized products. The company ...
Although the stock market was having a generally strong week, that isn't the case for vaccine technology company Moderna (NASDAQ: MRNA). The company, which was a leader in developing one of the ...
A bad seven-month stretch just got worse for Moderna (NASDAQ: MRNA). This update wasn't well-received by investors, and Moderna's share price sank nearly 17%. Moderna's stock chart certainly looks ...
Moderna's (NASDAQ: MRNA) wild success in the COVID-19 vaccine market has worn off. The company's revenue, earnings, and stock price have been moving in the wrong direction for the past three years ...
On Thursday, Moderna Inc (NASDAQ:MRNA) stock plunged as the company lowered its 2024 sales guidance due to weaker demand for its COVID-19 vaccines. Moderna now projects 2024 net sales of between ...
Moderna (NASDAQ: MRNA) ... Though the recent positive phase 3 data for mRNA-1083 is great news, investors should seriously consider buying the stock because of Moderna's innovative platform.